FR3008407A1 - ESTER AND GLYCINE BETAINE AMIDE DERIVATIVES AS DEODORANT ASSETS, COSMETIC COMPOSITIONS THAT INCLUDE THEM - Google Patents

Abstract

The invention relates to the use of at least one compound of formula (I) below or one of its optical isomers, as a deodorant agent in a composition, in particular a cosmetic composition. The invention also provides compositions comprising such a compound, devices comprising the composition, compounds as such, and a cosmetic method for treating body odor.

Description

The present invention relates to glycine-betaine esters and amide derivatives as deodorant active agents, cosmetic compositions comprising them, as well as their uses in cosmetics. SUMMARY OF THE INVENTION The present invention relates to glycine-betaine esters and amide derivatives. In particular, the present invention relates to a combination of glycine-betaine ester and amide derivatives with one or more deodorant active agents and / or one or more antiperspirant active agents.

In the cosmetic field, it is well known to use, in topical application, deodorant products containing active substances of the antiperspirant or deodorant type to reduce or even eliminate the generally unpleasant axillary odors. Deodorant substances usually destroy the resident bacterial flora.

Among these substances, the most used are Triclosan (2,4,4'-trichloro-2'-hydroxydiphenyl ether) and farnesol which have the disadvantage of significantly modifying the ecology of skin flora. There are substances that decrease the growth of bacteria. Among these substances, mention may be made of transition metal chelating agents such as EDTA or DPTA. These materials deprive the medium of metals necessary for the growth of bacteria. However, there remains the need to find new active ingredients that are effective in deodorant activity, including improving deodorant efficiency, while being easy to formulate as a product for reducing perspiration and / or odors, particularly in the be human, and more particularly to fight against body odors and more specifically axillary odors. Certain compounds of formula (I) are known from the prior art (eg Chemische Berichte, 1943, vol 76, p 15, 18). However, their known activities did not allow to consider preparing products intended to reduce perspiration and / or body odor in humans.

Chinese patent application CN86106630 discloses compositions comprising surfactants which would have deodorizing and sterilizing activity, but would be mainly used for the deodorization of toilets, farm pens, poultry houses, animal rearing rooms, and to eliminate bad odors produced by rotten food, the smell of fish and meat in the refrigerator, kitchen, food processing workshops, grocery stores and sewerage (abbreviated). The teaching of this application does not solve the problems posed by the present invention, these applications being very different from the treatment of odors or perspiration in a human being. It is also known that quaternary ammonium salts exhibit bactericidal activity (see AE EPSHTEIN et al .: "Bactericidal quaternary ammonium salts based on monochloroacetic acid esters", & Khim.-Farm, 1980, 14 (5), 23-6). Only the activity on microorganisms of the Escherichia coli or Staphylococcus aureus type are described. Thus the teaching of this document does not solve the problems posed by the present invention. International application WO 2005/044237 discloses beta-amine esters as surfactants in pharmaceutical compositions, especially for forming active ingredient delivery vectors. In addition, ester derivatives and betaine amides are described in US Pat. No. 2,888,383, as well as their synthesis. However, these compositions are particularly suitable for oral hygiene. These are in particular toothpastes.

International application WO 2006/105669 relates to products which have antimicrobial activity on Staphylococcus aureus, Bacillus cereus, Escherichia neck, Shigella sp., Salmonella sp. and Listeria monocytogenes or antifungal on different fungi. Finally, French application FR 2 869 913 describes surfactants comprising an ester or amide of glycine beta-1 for their detergent, emulsifying or foaming properties. This application describes in particular compositions of liquid soap, bubble bath, shower gel or shampoo. Thus, none of these prior documents can solve the technical problems that the present invention proposes to solve.

The inventors have surprisingly discovered that glycine-betaine ester and amide derivatives of formula (I) detailed below have good deodorant efficacy and can be easily formulated as a product intended to reduce body odor, alone, in particular. combination, or in combination with antiperspirants or conventional deodorant actives.

Thus, the invention relates to the use of a compound of formula (I), which will be given later in detail, as a deodorant agent in particular in a composition comprising a physiologically acceptable carrier. The subject of the present invention is also a composition, in particular a cosmetic composition, comprising in a physiologically acceptable medium at least one compound of formula (I) in combination with at least one antiperspirant active agent and / or at least one deodorant active agent.

The subject of the present invention is also a cosmetic method for treating body odors, in particular axillary odors, consisting in applying to the surface of the skin a composition comprising in a physiologically acceptable medium at least one compound of formula (I) or a composition containing it .

The present invention is particularly intended for the treatment of body odors of a human being. In particular, the present invention is intended for the treatment of axillary odors. The invention is described below in more detail.

Derivatives of glycine-betaine esters and amides The glycine-betaine derivatives in accordance with the invention are chosen from those corresponding to the following formula (I) and their optical isomers: ## STR1 ## where X represents an organic or inorganic anion; Y denotes 0 (oxygen atom, forming ester derivatives) or NR '(forming amide derivatives); R denotes: a linear or branched, saturated or unsaturated C 2 -C 22 alkyl radical; an aralkyl radical, in which the alkyl is in C1-022, linear or branched, saturated or unsaturated, in particular an aralkyl radical, the aryl part of which is a phenyl radical, optionally substituted with 1 to 4 linear C1-04 alkyl radicals; or branched; an aryl radical, in particular a phenyl radical optionally substituted with 1 to 4 linear or branched C1-C4 alkyl radicals; R 'denotes: a hydrogen atom; a linear or branched, saturated or unsaturated C 1 -C 22 alkyl radical; an aralkyl radical, in which linear or branched, saturated or unsaturated C1-C22 alkyl, in particular an aralkyl radical whose aryl part designates a phenyl radical, optionally substituted with 1 to 4 linear or branched C1-C4 alkyl radicals; ; an aryl radical, in particular a phenyl radical, optionally substituted with 1 to 4 linear or branched C1-C4 alkyl radicals.

X- for example, without this list being exhaustive: halide (such as for example chloride or bromide, preferably chloride), sulfate, methanesulfonate, citrate, lactate, acetate and any combination thereof. "Aryl" refers to a monocyclic or polycyclic aromatic hydrocarbon radical comprising from 5 to 22 carbon atoms such as, phenyl or naphthyl, and may optionally include one or more heteroatoms. The aryl radical may comprise one or more substituents, and in particular 1 to 4 linear or branched C1-C4 alkyl radicals. "Aralkyl" denotes an alkyl radical in which a hydrogen atom is substituted with an aryl radical, and in particular with a phenyl radical, optionally substituted with 1 to 4 linear or branched C1-C4 alkyl radicals. The aralkyl radical is bonded to Y by the alkyl radical. Among the compounds of formula (I), and their optical isomers, the compounds are preferably chosen for which: R denotes a linear or branched, saturated or unsaturated C 2 -C 22 alkyl radical; Y represents 0 or NR '; R 'denotes: 0 a hydrogen atom 0 a linear or branched, saturated or unsaturated C 1 -C 22 alkyl radical. Preferably, R and / or R 'denotes a linear or branched, saturated or unsaturated 02-022 alkyl. Among the compounds of formula (I), or one of its optical isomers, the compounds in which R 1 denotes a linear or branched, saturated or unsaturated C 2 -C 22 alkyl radical and / or Y represents 0 or NH. Among the compounds of formula (I), the following compounds, or their optical isomers, are chosen more particularly: TABLE 1 Compounds Structure C H3 H3c (j, 1; kO \ N ±, cF_13 x-cH3 1 0 cH3 1 0 C) ## STR2 ## 1 + 3 X- 0 --- Y-CI-13 CH3 2 0 0 I \\ _ -IS-0 I 0 H3C 0 CH ## STR2 ## ## STR2 ## ## STR1 ## ## STR2 ## wherein: ## STR2 ## ## STR5 ## wherein R 1 is OCH 3 X-H 3 C 0 6 0 0 II - 0/7 I ci -Ni ----- r .. O 0 P-13 X- 0 / N ---- cH 3 H3C 8 il 0 / + 0 0 / N ---. ## STR2 ## wherein -i3 CH3 10? ## STR1 ## CH, 1 CH, CH, 12 X- having the same meaning as above. The invention also relates to compounds of formula (I), their optical isomers. In particular, the invention relates to compounds which have not been described hitherto in the prior art. More particularly, the invention relates to a compound below or an optical isomer thereof: wherein same meaning as before; Z- 0, Z- representing an organic or inorganic anion except chloride, and preferably selected from bromide, sulfate, methanesulfonate, citrate, lactate, acetate, and any combination thereof. In particular, the invention relates to the following compounds: ## STR5 ## These are the methanesulphonate salts of the abovementioned compounds. More particularly, the invention relates to the following compound, and in particular its methanesulphonate salt: ## STR1 ## The invention also relates to combinations of two or more formula (I). By the term "according to the invention" is meant any of the embodiments or variants, including those general and those more specific or preferred and combinations thereof, this reference to be interpreted in the broadest sense.

A compound is considered to possess deodorant properties on resident bacterial strength. The activity of such a compound can be tested on Corynebacterium xerosis strains. A compound is considered active when it reduces the number of revivable bacteria germs by several log, preferably at least 3 log relative to a reference sample in which the test compounds are not present. The present invention also relates to the preparation of compounds defined according to the invention. Since some of the compounds of formula (I) are known from the prior art, those skilled in the art can rely on the literature for the preparation of all the compounds of formula (I) of the invention. Synthetic synthesis schemes are as follows: Preparation of ester derivatives (Y = 0) The glycine-betaine ester derivatives (I) which are the subject of the present invention can be obtained, for example, in two stages from glycine betaine. (A): using the alcohol ROH as a solvent, acidification of the betaine initially in zwitterionic form with an excess of HX acid and then esterification of the mixture thus obtained (presence of residual HX acid), for example with a 60.degree. 160 ° C. (6) ## STR2 ## Amides (Y = NR ') The glycine-betaine amide derivatives (I) which are the subject of the present invention can be obtained, for example, in three steps from glycine betaine (A): activation of glycine betaine (A). ) in the form of the corresponding acyl chloride substitution of chlorine by 2-mercaptothiazoline in basic medium (obtaining the intermediate (B)) transamidation with the amine RR'NH CI H NÂS CI CH2Cl2 TEA N. ') / The invention also relates to compositions, in particular cosmetics, in particular having a deodorant and optionally antiperspirant, comprising a physiologically acceptable medium. The invention relates in particular to a composition, in particular a cosmetic composition comprising, in a physiologically acceptable medium, at least one compound of formula (I) according to the invention, in combination with at least one antiperspirant active agent and / or at least one other deodorant active agent. in a physiologically acceptable medium.

For the purposes of the present invention, the term "physiologically acceptable medium" means a medium suitable for the administration of a composition topically. A physiologically acceptable medium is preferably a cosmetically or dermatologically acceptable medium, that is to say without odor, or unpleasant appearance, and which is perfectly compatible with the topical route of administration. In the present case where the composition is intended to be administered topically, that is to say by surface application of the keratin material in question, such a medium is in particular considered physiologically acceptable when it does not generate tingling, tugging or redness unacceptable to the user. Advantageously, the composition according to the invention comprises one or more other deodorant active agents and / or one or more antiperspirant active agents. For the purposes of the present invention, the term "deodorant active agent" is intended to mean any active ingredient which, by itself, has the effect of masking, absorbing, improving and / or reducing the unpleasant odor resulting from the decomposition of human sweat. An active agent and a deodorant agent have an equivalent meaning according to the present invention. By "antiperspirant active" we mean any substance which, by itself, has the effect of reducing the flow of sweat, of reducing the sensation on the skin of moisture linked to human sweat, of masking human sweat. An antiperspirant active and an anti-perspirant agent have an equivalent meaning according to the present invention. Cosmetic composition Additional deodorant active agents The composition according to the invention may contain one or more additional deodorant active agents other than the compounds according to the invention, for example: bacteriostatic agents or other bactericidal agents such as 2,4,4 trichloro-2'-hydroxydiphenyl ether (Triclosan), 2,4-dichloro-2'-hydroxydiphenyl ether, 3 ', 4', 5'-trichlorosalicylanilide, 1 - (- 3 ', 4'-dichlorophenyl) - 3- (4'-chlorophenyl) urea (Triclocarban) or 3,7,11-trimethyldodeca-2,5,10-trienol (Farnesol); quaternary ammonium salts such as cetyltrimethylammonium salts, cetylpyridinium salts; chlorhexidine and salts; diglycerol monocaprate, diglycerol monolaurate, glycerol monolaurate; polyhexamethylene biguanide salts; zinc salts such as zinc salicylate, zinc phenolsulfonate, zinc pyrrolidone carboxylate (more commonly known as zinc pidolate), zinc sulphate, zinc chloride, zinc lactate, zinc gluconate, zinc ricinoleate, zinc glycinate, zinc carbonate, zinc citrate, zinc chloride, zinc laurate, zinc oleate, zinc orthophosphate, zinc steroid, zinc tartrate, acetate zinc or mixtures thereof; odor absorbers such as zeolites, cyclodextrins, metal oxide silicates such as those described in the application US2005 / 063928; transition metal-modified metal oxide particles as described in US2005084464 and US2005084474, aluminosilicates such as those described in EP1658863, particles of chitosan derivatives such as those described in US6916465; substances blocking the enzymatic reactions responsible for the formation of odorous compounds such as arylsulfatase, 5-lipoxygenase, aminocyclase and 13-glucoronidase inhibitors; and their mixtures. The deodorant active agents (including the compounds according to the invention) may be present in the composition according to the invention in a proportion of from 0.01 to 20% by weight relative to the total weight of the composition, and preferably to 0.1 to 10% by weight Antiperspirant active agents The composition according to the invention may contain one or more antiperspirant active agents The antiperspirant active agents are preferably chosen from aluminum salts and / or zirconium, complexes of zirconium hydroxychloride and of aluminum hydroxychloride with an amino acid such as those described in US-3792068. Such complexes are generally known by the name ZAG (when the amino acid is the Glycine) ZAG complexes typically have an Al / Zr quotient ranging from about 1.67 to 12.5 and a Metal / CI quotient ranging from about 0.73 to 1.93. zirconium aluminum octachlorohydrex GLY, aluminum zirconium pentachlor ohydrex GLY, aluminum zirconium tetrachlorohydrate GLY and aluminum zirconium trichlorohydrate-GLY.

Among the aluminum salts, mention may be made of aluminum chlorohydrate, chlorohydroxyl aluminum, chlorohydroxyl aluminum PEG, aluminum chlorohydrex PG, aluminum dichlorohydrate, aluminum dichlorohydrex PEG, aluminum dichlorohydrex PG, aluminum sesquichlorohydrate, aluminum sesquichlorohydrex PEG, aluminum sesquichlorohydrex PG, alum salts, aluminum sulfate, aluminum zirconium octachlorohydrate, aluminum zirconium pentachlorohydrate, aluminum zirconium tetrachlorohydrate, aluminum zirconium trichlorohydrate and more particularly the aluminum hydroxychloride sold by the company REHEIS under the name REACH 301® or by the company GUILINI CHEMIE under the name ALOXICOLL PF 400. Aluminum salts and zirconium are for example that marketed by the company REHEIS under the name REACH AZP-908-SUF®.

Aluminum chlorohydrate in activated or non-activated form will be used more particularly. The antiperspirant active agents may be present in the composition according to the invention in a proportion of 0.001 to 30% by weight relative to the total weight of the composition and preferably in a proportion of 0.5 to 25% by weight. in weight.

Dosage forms The composition according to the invention may be in any of the galenical forms conventionally used for topical application and especially in the form of aqueous gels, aqueous or aqueous-alcoholic solutions. They can also, by addition of a fatty or oily phase, be in the form of lotion-type dispersions, emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase. (W / O) or conversely (W / O), or suspensions or emulsions of soft, semi-solid or solid consistency of the cream or gel type, or multiple emulsions (W / O / W or H / E / H), microemulsions, vesicular dispersions of ionic and / or nonionic type, or wax / aqueous phase dispersions. These compositions are prepared according to the usual methods. The compositions may in particular be packaged in pressurized form in an aerosol device or in a pump bottle; packaged in a device provided with a perforated wall including a grid; packaged in a device equipped with a roll-on applicator, packaged in the form of sticks (sticks), in the form of loose or compacted powder, in this respect they contain the ingredients generally used in this type of product and Well known to those skilled in the art According to another particular form of the invention, the compositions according to the invention can be anhydrous.

By anhydrous composition is meant a composition containing less than 2% by weight of water, or even less than 0.5% of water, and in particular water-free, the water not being added. during the preparation of the composition but corresponding to the residual water provided by the mixed ingredients.

According to another particular form of the invention, the compositions according to the invention can be solid, in particular in the form of a stick or a stick. By "solid composition" it is meant that the measurement of the maximum force measured in texturometry during the insertion of a probe into the sample of formula must be at least 0.25 Newton, in particular at least equal to 0.30 Newton, especially at least 0.35 Newton, appreciated under precise measurement conditions as follows. The formulas are poured hot in pots 4 cm in diameter and 3 cm deep. Cooling is done at room temperature. The hardness of the formulas is measured after 24 hours of waiting. The pots containing the samples are characterized in texturometry using a texturometer such as that marketed by Rhéo TA-XT2, according to the following protocol: a ball-type stainless steel probe of diameter 5 mm is brought into contact with the sample at a speed of 1 mm / s. The measurement system detects the interface with the sample with a detection threshold equal to 0.005 newtons. The probe sinks 0.3 mm into the sample at a rate of 0.1 mm / s. The meter records the evolution of the force measured in compression over time, during the penetration phase. The hardness of the sample corresponds to the average of the maximum values of the force detected during the penetration, on at least 3 measurements.

Aqueous phase The compositions according to the invention intended for cosmetic use may comprise at least one aqueous phase. They are in particular formulated in aqueous lotions or in water-in-oil, oil-in-water or multiple emulsion emulsions (triple oil-in-water-in-oil or water-in-oil-in-water emulsion). such emulsions are known and described for example by C. FOX in "Cosmetics and Toiletries" - november 1986 - Vol 101 - pages 101-112) .The aqueous phase of said compositions contains water and in general other soluble solvents or miscible in water Solvents that are soluble or miscible in water include short-chain monohydric alcohols, for example C 1 -C 4, such as ethanol, isopropanol, diols or polyols, such as ethylene glycol, and the like. , 2-propylene glycol, 1,3-butylene glycol, hexylene glycol, diethylene glycol, dipropylene glycol, 2-ethoxyethanol, diethylene glycol monomethyl ether, triethylene glycol monomethyl ether and sorbitol, more particularly propylene glycol and glycerin, propane 1,3 di ol.

The composition according to the invention preferably has a pH ranging from 3 to 9 depending on the support chosen. Emulsifiers Oil-in-Water Emulsifiers As emulsifiers that can be used in oil-in-water emulsions or oil-in-water-in-oil triple emulsions, mention may be made, for example, of nonionic emulsifiers such as fatty acid esters. and oxyalkylenated glycerol (more particularly polyoxyethylenated); oxyalkylenated fatty acid and sorbitan esters; oxyalkylenated fatty acid esters (oxyethylenated and / or oxypropylenated); oxyalkylenated fatty alcohol ethers (oxyethylenated and / or oxypropylenated); sugar esters such as sucrose stearate; and mixtures thereof such as the mixture of glyceryl stearate and PEG-40 stearate.

Mention may also be made of the fatty alcohol / alkylpolyglycoside emulsifying mixtures as described in the applications WO92 / 06778, WO95 / 13863 and WO98 / 47610, such as the commercial products sold by the company SEPPIC under the names MONTANOV O.

Water-in-oil Emulsifiers Among the emulsifiers that can be used in water-in-oil emulsions or triple emulsions, mention may be made by way of example of alkyl dimethicone copolyols such as Cetyl PEG / PPG-10/1 DIMETHICONE and more particularly the Cetyl PEG / PPG-10/1 mixture DIMETICONE and Dimethicone (INCI name), such as the product sold under the trade name ABIL EM90® by GOLDSCHMIDT or the mixture (Polyglyceryl-4-stearate and Cetyl PEG / PPG-10 ( and) Dimethicone (and) Hexyl Laurate) as the product sold under the trade name ABIL WE09® by the same company. Among the water-in-oil emulsifiers, mention may also be made of dimethicone copolyols such as PEG-18 / PPG-18 Dimethicone and more particularly the mixture CYCLOPENTASILOXANE (and) PEG-18 / PPG-18 Dimethicone (INCI name) such as the product sold by Dow Corning under the trade name Silicone DC 5225 Ce or KF-6040® from Shin Etsu. Among the water-in-oil emulsifiers, mention may also be made of nonionic emulsifiers derived from fatty acid and polyol, alkylpolyglycosides (APG), sugar esters and mixtures thereof. As nonionic emulsifiers derived from fatty acid and polyol, it is possible in particular to use the fatty acid and polyol esters, the fatty acid having in particular a C 8 -C 24 alkyl chain, and the polyols being, for example, glycerol and sorbitan. Examples of fatty acid and polyol esters that may be mentioned include esters of isostearic acid and of polyols, esters of stearic acid and of polyols, and mixtures thereof, in particular esters of isostearic acid and of glycerol, and / or sorbitan. As esters of stearic acid and of polyols, mention may in particular be made of polyethylene glycol esters such as PEG-30 dipolyhydroxystearate, such as the product sold under the name Arlacel P135® by the company ICI.

Examples of glycerol and / or sorbitan esters that may be mentioned are polyglycerol isostearate, such as the product sold under the name Isolan GI 34® by the company Goldschmidt; sorbitan isostearate, such as the product sold under the name Arlacel 987 by the company ICI; sorbitan isostearate and glycerol, such as the product sold under the name Arlacel 986® by the company ICI, the mixture of sorbitan isostearate and polyglycerol isostearate (3 moles) sold under the name Arlacel 169® by the company Unigema, and their mixtures. The emulsifier can also be chosen from alkylpolyglycosides having an HLB of less than 7, for example those represented by the following general formula (1): R'-O- (G) x (1) in which R 'represents an alkyl radical branched and / or unsaturated, having from 14 to 24 carbon atoms, G represents a reduced sugar having from 5 to 6 carbon atoms, and x represents a value ranging from 1 to 10 and preferably from 1 to 4, and G designates especially glucose, fructose or galactose. The unsaturated alkyl radical may comprise one or more ethylenic unsaturations, and in particular one or two ethylenic unsaturations.

As alkylpolyglycosides of this type, mention may be made of alkylpolyglucosides (G = glucose in formula (I)), and in particular the compounds of formula (I) in which R represents more particularly an oleyl radical (unsaturated radical at 018) or isostearyl radical ( saturated radical at 018), G denotes glucose, x is a value ranging from 1 to 2, especially isostearyl glucoside, oleyl glucoside and mixtures thereof. This alkylpolyglucoside may be used in admixture with a co-emulsifier, more particularly with a fatty alcohol and in particular a fatty alcohol having the same fatty chain as that of the alkylpolyglucoside, that is to say comprising from 14 to 24 carbon atoms. carbon and having a branched and / or unsaturated chain, and for example isostearyl alcohol when the alkylpolyglucoside is isostearylglucoside, and oleyl alcohol when the alkylpolyglucoside is oleylglucoside, optionally in the form of a self-emulsifying composition, as described for example in WO-A-92/06778. Mention may also be made of succinic-terminated polyolefins, such as ester-terminated polyisobutylenes and their salts, especially diethanolamine salts, such as the products sold under the names Lubrizol 27240, Lubrizol 2722® and Lubrizol 5603 by the company Lubrizol® or the commercial product CHEMCINNATE 20000. The total amount of emulsifiers will preferably be in the composition according to the invention at contents of active ingredient ranging from 1 to 8% by weight and more particularly from 2 to 6% by weight relative to the total weight. of the composition.

Fatty phase The compositions according to the invention may contain at least one immiscible organic liquid phase in water called the fatty phase. This generally comprises one or more hydrophobic compounds which render said phase immiscible in water.

Said phase is liquid (in the absence of structuring agent) at room temperature (20-25 ° C). Preferably, the immiscible organic liquid phase in water according to the invention generally comprises at least one volatile oil and / or a non-volatile oil and optionally at least one structuring agent. The term "oil" means a fatty substance that is liquid at ambient temperature (25 ° C.) and atmospheric pressure (760 mm Hg, ie 1.05 × 10 5 Pa). The oil may be volatile or non-volatile. For the purposes of the invention, the term "volatile oil" means an oil capable of evaporating on contact with the skin or keratin fiber in less than one hour at ambient temperature and atmospheric pressure. The volatile oils of the invention are volatile cosmetic oils which are liquid at ambient temperature and have a non-zero vapor pressure at ambient temperature and atmospheric pressure, in particular ranging from 0.13 Pa to 40,000 Pa (10-3 to 300 mmHg), in particular ranging from 1.3 Pa to 13 000 Pa (0.01 to 100 mmHg), and more particularly ranging from 1.3 Pa to 1300 Pa (0.01 to 10 mmHg). ). By "non-volatile oil" is meant an oil remaining on the skin or the keratinous fiber at room temperature and atmospheric pressure for at least several hours and in particular having a vapor pressure of less than 10 -3 mmHg (0.13 Pa). . The oil may be chosen from all physiologically acceptable and in particular cosmetically acceptable oils, in particular mineral, animal, vegetable, and synthetic oils; in particular volatile and / or nonvolatile hydrocarbon and / or silicone and / or fluorinated oils and mixtures thereof. More precisely, the term "hydrocarbon-based oil" means an oil comprising mainly carbon and hydrogen atoms and optionally one or more functional groups chosen from hydroxyl, ester, ether and carboxylic functions. Generally, the oil has a viscosity of 0.5 to 100,000 mPa.s, preferably 50 to 50,000 mPa.s and more preferably 100 to 300,000 mPa.s. By way of example of volatile oil that can be used in the invention, mention may be made of: volatile hydrocarbon oils chosen from hydrocarbon-based oils having 8 to 16 carbon atoms, and in particular 08-016 isoalkanes of petroleum origin ( also called isoparaffins) such as isododecane (also called 2,2,4,4,6-pentamethylheptane), isodecane, isohexadecane, and for example the oils sold under the trade names of Isopars or permetyls, 08-016 branched esters, isohexyl neopentanoate, and mixtures thereof. Other volatile hydrocarbon oils such as petroleum distillates, in particular those sold under the name Shell or by Shell, may also be used; volatile linear alkanes such as those described in the patent application of Cognis DE10 2008 012 457. volatile silicones, such as, for example, volatile linear or cyclic silicone oils, in particular those having a viscosity of 8 centistokes (8 10-6 m2 / s), and having in particular 2 to 7 silicon atoms, these silicones optionally comprising alkyl or alkoxy groups having from 1 to 10 carbon atoms. As volatile silicone oil that can be used in the invention, there may be mentioned in particular octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane, heptamethylhexyltrisiloxane, heptamethyloctyltrisiloxane, hexamethylisiloxane, octamethyltrisiloxane and decamethyl tetrasiloxane, dodecamethylpentasiloxane - and mixtures thereof.

It is also possible to mention volatile alkyltrisiloxane linear oils of general formula (I): ## STR1 ## where R represents an alkyl group comprising from 2 to 4 carbon atoms and one of which or more than one hydrogen atom may be substituted with a fluorine or chlorine atom. Among the oils of general formula (I), mention may be made of: 3-butyl 1,1,1,3,5,5,5-heptamethyltrisiloxane, 3-propyl 1,1,1,3,5,5 , 5-heptamethyltrisiloxane, and 3-ethyl-1,1,1,3,5,5,5-heptamethyltrisiloxane, corresponding to the oils of formula (I) for which R is respectively a butyl group, a propyl group or a ethyl group.

As an example of a non-volatile oil that may be used in the invention, mention may be made of: hydrocarbon-based oils of animal origin, such as perhydrosqualene; vegetable hydrocarbon-based oils such as liquid triglycerides of fatty acids with 4 to 24 carbon atoms, for instance triglycerides of heptanoic or octanoic acids or oils, wheat germ oils, olive oil and almond oil sweet, palm, colza, cotton, alfalfa, poppy, pumpkin, squash, black currant, evening primrose, millet, barley, quinoa, rye, safflower, bancoulier, passionflower, muscat rose, sunflower, maize, soya, squash, grape seed, sesame, hazelnut, apricot, macadamia, castor oil, avocado, caprylic / capric acid triglycerides as those sold by the company Stearineries Dubois or those sold under the names Miglyol 810, 812 and 818 by the company Dynamit Nobel, jojoba oil, shea butter; linear or branched hydrocarbons of mineral or synthetic origin, such as paraffin oils and their derivatives, petroleum jelly, polydecenes, polybutenes, hydrogenated polyisobutene such as Parleam or squalane; synthetic ethers having from 10 to 40 carbon atoms; synthetic esters, especially of fatty acids, such as the oils of formula R1000R2 in which R1 represents the residue of a linear or branched higher fatty acid containing from 1 to 40 carbon atoms, and R2 represents a hydrocarbon chain, in particular branched, containing 1 at 40 carbon atoms with R1 + R2 such as, for example, purcellin oil (cetostearyl octanoate), isononyl isononanoate, isopropyl myristate, isopropyl palmitate, 012 alcohol benzoate at 015, hexyl laurate, diisopropyl adipate, ethyl 2-hexyl palmitate, octyl 2-dodecyl stearate, octyl 2-dodecyl erucate, isostearyl isostearate, tridecyl trimellitate; octanoates, decanoates or ricinoleates of alcohols or polyalcohols such as propylene glycol dioctanoate; hydroxyl esters such as isostearyl lactate, octyl hydroxy stearate, octyl dodecyl hydroxystearate, diisostearyl malate, triisocetyl citrate, heptanoates, octanoates, decanoates of fatty alcohols; polyol esters such as propylene glycol dioctanoate, neopentyl glycol diheptanoate, diethylene glycol diisononanoate; and pentaerythritol esters such as pentaerythritol tetraisostearate; branched-chain and / or unsaturated carbon-chain liquid fatty alcohols having from 12 to 26 carbon atoms, such as octyl dodecanol, isostearyl alcohol, 2-butyloctanol, 2-hexyl decanol and 2-undecyl; pentadecanol, oleic alcohol; higher fatty acids such as oleic acid, linoleic acid, linolenic acid; - carbonates; - acetates; - citrates; fluorinated oils that may be partially hydrocarbon-based and / or silicone-based, such as fluorosilicone oils, fluorinated polyethers or fluorinated silicones, as described in document EP-A-847752; silicone oils, such as non-volatile, linear or cyclic polydimethylsiloxanes (PDMS); polydimethylsiloxanes comprising alkyl, alkoxy or phenyl groups, during or at the end of the silicone chain, groups having from 2 to 24 carbon atoms; phenyl silicones such as phenyl trimethicones, phenyl dimethicones, phenyl trimethylsiloxy diphenyl siloxanes, diphenyl dimethicones, diphenyl methyldiphenyl trisiloxanes, 2-phenyl ethyl trimethyl siloxysilicates, and mixtures thereof. Additives The cosmetic compositions according to the invention may be furthermore comprise cosmetic adjuvants chosen from softeners, antioxidants, opacifiers, stabilizers, moisturizing agents, vitamins, bactericides, preservatives, polymers, perfumes, a structuring agent for the fatty phase, chosen in particular from the waxes, pasty compounds, gelling agents; organic or inorganic fillers; thickeners or suspending agents, propellants or any other ingredient usually used in cosmetics for this type of application. Of course, those skilled in the art will take care to choose this or these optional additional compounds in such a way that the advantageous properties intrinsically attached to the cosmetic composition in accordance with the invention are not, or not substantially, impaired by the addition or additions envisaged. .

Wax (s) Wax is generally a solid, reversible solid state / liquid reversible solid state (25 ° C) lipophilic compound having a melting point greater than or equal to 30 ° C up to 200 ° C and especially up to 120 ° C.

In particular, the waxes that are suitable for the invention may have a melting point greater than or equal to 45 ° C., and in particular greater than or equal to 55 ° C. For the purposes of the invention, the melting temperature corresponds to the temperature of the most endothermic peak observed in thermal analysis (DSC) as described in ISO 11357-3; 1999. The melting point of the wax can be measured using a differential scanning calorimeter (DSC), for example the calorimeter sold under the name "MDSC 2920®" by the company TA Instruments. The measurement protocol is as follows: A sample of 5 mg of wax placed in a crucible is subjected to a first temperature rise from -20 ° C to 100 ° C, at the heating rate of 10 ° C / minute, then cooled from 100 ° C to -20 ° C at a cooling rate of 10 ° C / minute and finally subjected to a second temperature rise from -20 ° C to 100 ° C at a heating rate of 5 ° C / minute. During the second temperature rise, the variation of the power difference absorbed by the empty crucible and the crucible containing the wax sample as a function of temperature is measured. The melting point of the compound is the value of the temperature corresponding to the peak apex of the curve representing the variation of the difference in power absorbed as a function of the temperature. The waxes that may be used in the compositions according to the invention are chosen from waxes, solid, at room temperature of animal, vegetable, mineral or synthetic origin, and mixtures thereof. Illustrative waxes suitable for the invention include hydrocarbon waxes such as beeswax, lanolin wax, and Chinese insect wax, rice bran wax, Carnauba wax Candellila wax, Ouricury wax, Alfa wax, berry wax, shellac wax, Japanese wax and sumac wax; montan wax, orange and lemon waxes, refined sunflower wax sold under the name SUNFLOWER WAX® by KOSTER KEUNEN, microcrystalline waxes, paraffins and ozokerite; polyethylene waxes, waxes obtained by Fisher-Tropsch synthesis and waxy copolymers and their esters. There may also be mentioned waxes obtained by catalytic hydrogenation of animal or vegetable oils having linear or branched C5-C32 fatty chains. Among these, there may be mentioned isomerized jojoba oil such as trans isomerized partially hydrogenated jojoba oil manufactured or marketed by Desert Whale under the trade reference Iso-Jojoba-500, hydrogenated sunflower oil hydrogenated castor oil, hydrogenated coconut oil, hydrogenated lanolin oil, and di- (trimethyl-1,1,1-propane) tetrastearate sold under the name Hest 2T-4S® by the HETERENE company. Mention may also be made of silicone waxes (C30-45 ALKYL DIMETHICONE) and fluorinated waxes. It is also possible to use the waxes obtained by hydrogenation of castor oil esterified with cetyl alcohol sold under the names Phytowax Ricin 16L64® and 22L73® by the company SOPHIM. Such waxes are described in the application FR-A-2792190. As wax, a C20-C40 alkyl (hydroxystearyloxy) stearate (the alkyl group comprising from 20 to 40 carbon atoms) can be used, alone or as a mixture . Such a wax is sold, for example, under the names "Kester Wax K 82 P", "Hydroxypolyester K 82 P®" and "Kester Wax K 80 P®" by the company Koster Keunen. As micro-waxes that may be used in the compositions according to the invention, mention may be made in particular of carnauba micro-waxes such as that marketed under the name MicroCare 350® by the company Micro Powders, synthetic wax waxes such as that marketed under the name MicroEase 114Se by the company MICRO POWDERS, micro waxes consisting of a mixture of carnauba wax and polyethylene wax such as those sold under the names Micro Care 3000 and 3100 by the company Micro Powders, micro waxes consisting of a mixture of carnauba wax and synthetic wax such as that sold under the name Micro Care 3250 by the company Micro Powders, polyethylene micro-waxes such as those sold under the names Micropoly 200e, 220e, 220Le and 250Se by the company MICRO POWDERS, commercial products PERFOMALEN 400 POLYETHYLEN Ee and PERFORMALENE 500-L POLYETHYLENEe from NEW PHASE TECHNOLOGIES, PERFORMALENE 655 POLYETHYLENE or paraffin waxes such as wax INCI, MICROCRYSTALLINE WAX and SYNTHETIC WAX and sold under the trade name MICROLEASE by the company SOCHIBO. ; polytetrafluoroethylene micro waxes such as those sold under the names Microslip 5190 and 519 by the company MICRO POWDERS. Paste compounds For the purposes of the present invention, the term "pasty compound" is intended to mean a lipophilic fat compound with a reversible solid / liquid state change, having in the solid state an anisotropic crystalline organization and having at a temperature of 23 ° C. a liquid fraction and a solid fraction. The pasty compound is preferably chosen from synthetic compounds and compounds of plant origin. A pasty compound can be obtained synthetically from starting materials of plant origin.

The pasty compound may advantageously be chosen from: lanolin and its derivatives, silicone compounds which may or may not be polymeric, fluorinated compounds which may or may not be polymeric, vinyl polymers, in particular: homopolymers of olefins, copolymers of olefins, - homopolymers and copolymers of hydrogenated dienes, - linear or branched oligomers, homo or copolymers of alkyl (meth) acrylates preferably having a C8-C30 alkyl group, - homo and copolymer oligomers of esters vinyls having C8-C30 alkyl groups, and homo- and copolymer oligomers of vinyl ethers having 08-030 alkyl groups; liposoluble polyethers resulting from the polyetherification between one or more C2-C10, preferably O2 diols; -050, - the esters, - their mixtures. Suspension Agents / Gelling Agents The composition according to the invention may further contain one or more suspending agents and / or one or more gelling agents. Some of them can play both roles at once. Among the agents that can be used as suspending agent and / or as lipophilic gelling agent, there may be mentioned optionally modified clays, in particular hydrophobic modified montmorillonite clays, such as hydrophobic modified bentonites or hectorites, such as hectorites modified with an ammonium chloride in the form of 022, such as hectorite modified with di-stearyl dimethyl ammonium chloride such as, for example, the product Disteardimonium Hectorite (CTFA name) (reaction product of hectorite and distearyldimonium chloride) sold under the name Bentone 38 or Bentone Gel by Elementis Specialties. Mention may be made, for example, of the product Stearalkonium Bentonite (CTFA name) (reaction product of bentonite and of quaternary ammonium stearalkonium chloride), such as the commercial product sold under the name Tixogel MP 250® by the company Sud Chemie Rheologicals, United Catalysts Inc.

It is also possible to use hydrotalcites, in particular hydrophobic modified hydrotalcites, for example the products sold under the name Gilugel by the company BK Giulini. It is also possible to mention fumed silica optionally treated with hydrophobic surfaces whose particle size is less than 11 μm. It is indeed possible to chemically modify the surface of the silica, by chemical reaction generating a decrease in the number of silanol groups present on the surface of the silica. In particular, it is possible to substitute silanol groups with hydrophobic groups: a hydrophobic silica is then obtained. The hydrophobic groups may be trimethylsiloxyl groups, which are especially obtained by treatment of fumed silica in the presence of hexamethyldisilazane. Silicas thus treated are called "Silica silylate" according to the CTFA (8th edition, 2000). They are for example sold under the references Aerosil R812® by the company Degussa, CAB-0-SIL TS-530® by CABOT, dimethylsilyloxyl or polydimethylsiloxane groups, which are especially obtained by treatment of fumed silica in the presence of polydimethylsiloxane or dimethyldichlorosilane. Silicas thus treated are called "Silica dimethyl silylate" according to the CTFA (8th edition, 2000). They are for example marketed under the references Aerosil R972®, and Aerosil R974® by the company DEGUSSA, CAB-O-SIL TS-610® and CAB-O-SIL TS-720® by CABOT. The hydrophobic fumed silica has in particular a particle size that can be nanometric to micrometric, for example ranging from about 5 to 200 nm. Other suspending agents or gelling agents may be used, in this case in hydrophilic media (aqueous and / or ethanolic). These are cellulosic derivatives (which may be microcrystalline), xanthan, guar starch (including modified corn starch marketed under the name Structure XL by Akzo Nobel), carob, agar agar. The amounts of these various constituents that may be present in the composition according to the invention are those conventionally used in compositions, especially for the treatment of perspiration and / or body odor.

Aerosols The compositions according to the invention may be pressurized and packaged in an aerosol device consisting of: (A) at least one container comprising a composition according to the invention, (B) at least one propellant and at least one means of distribution of said composition in aerosol form. Propellants generally used in this type of product and well known to those skilled in the art are, for example, dimethyl ether (DME); volatile hydrocarbons such as n-butane, propane, isobutane, and mixtures thereof, optionally with at least one chlorinated and / or fluorinated hydrocarbon; among these are the compounds sold by the company Dupont de Nemours under the names Freon® and Dymel®, and in particular monofluorotrichloromethane, difluorodichloromethane, tetrafluorodichloroethane and 1,1-difluoroethane sold in particular under the trade name Dymel 152 A® by DUPONT. It is also possible to use as propellant carbon dioxide, nitrous oxide, nitrogen or compressed air.

The compositions containing the perlite particles as defined above and the propellant (s) may be in the same compartment or in different compartments in the aerosol container. According to the invention, the concentration of propellant generally varies from 5 to 95% by weight pressurized and more preferably from 50 to 85% by weight relative to the total weight of the pressurized composition. The dispensing means, which forms part of the aerosol device, is generally constituted by a dispensing valve controlled by a dispensing head, itself comprising a nozzle through which the aerosol composition is vaporized. The container containing the pressurized composition may be opaque or transparent. It may be glass, polymeric material or metal, optionally covered with a layer of protective varnish. The invention also relates to a packaging ("packaging") or information notice comprising, possibly among other visual information, the mention of the presence of one or more of the compounds according to the invention, and / or the presence of at least one antiperspirant active agent and / or at least one other deodorant active agent. In particular the invention relates to a package or information notice comprising the list of ingredients of a composition according to the present invention. According to one variant, the packaging or the information leaflet presents visual information concerning the treatment of odors and / or perspiration, in particular in a human being. More particularly, this packaging or information notice is intended to inform a user of the destination of the composition or device according to the invention, already packaged or which should be packed therein. The invention also relates to a composition according to the invention, or a device comprising it, accompanied by a packaging or information notice, particularly as defined above. The invention relates in particular to a composition, in particular a cosmetic composition, comprising in a physiologically acceptable medium at least one compound of formula (I) according to the invention, optionally in combination with at least one antiperspirant active agent and / or at least one other deodorant active agent in a physiologically acceptable medium, said composition being accompanied by a package or information notice presenting visual information concerning the treatment of odors and / or perspiration of a human being, and / or information on the presence of less an antiperspirant active and / or at least one deodorant active, possibly among other visual information. Expressions "between ... and ..." and "from ... to ..." must be understood as inclusive terms unless otherwise specified.

The following examples illustrate the present invention without limiting its scope. In the examples, the temperature is that ambient (20-25 ° C), the pressure is atmospheric (101 325 Pa), unless otherwise indicated. The mass of ingredients is expressed as a percentage relative to the mass of the total composition considered.

EXAMPLES EXAMPLE 1 Preparation of Compound 3 A mixture of betaine (A) (2 g, 16.9 mmol), 1-decanol (8 ml) and Methanesulfonic acid (1.4 ml) is heated at 140 ° C. for 8 hours under an inert atmosphere (N 2). After returning to ambient temperature, the excess of acid is neutralized by adding a saturated aqueous solution of betaine. This mixture is then concentrated to dryness by evaporation under reduced pressure. The residue is taken up in acetone to redissolve the product. After filtration of the betaine salts, the filtrate is concentrated by evaporation under reduced pressure. The crude reaction product is purified by recrystallization from n-heptane. The product is thus isolated in the form of a white solid. (2.6g - 44% yield). The 1 H NMR spectrum and the mass spectrum confirm the structure of the expected compound 3. 1H NMR (MeOD): 0.85-0.94 (m, 3H); 1.20-1.48 (m, 14H); 1.60-1.80 (m, 2H); 2.69 (s, 3H); 3.33 (s, 9H); 4.25 (t, 2H); 4.38 (s, 2H) Spectrom. mass: detected = 258 - expected for [C15H32NO2] ± = 258 EXAMPLE 2: Preparation of Compound 2 1-13c CH 3 3C-S-OCH 3 A mixture of betaine (A) (24g, 0.2mol), 3-octanol (60mL) and methanesulfonic acid (18mL) is heated at 140 ° C for 8h under an inert atmosphere (N2). After returning to ambient temperature, the excess of acid is neutralized by adding a saturated aqueous solution of betaine. This mixture is then concentrated to dryness by evaporation under reduced pressure. The residue is taken up in acetone to redissolve the product. After filtration of the betaine salts, the filtrate is concentrated by evaporation under reduced pressure. The compound thus obtained is purified by recrystallization from n-heptane. The product 2 is thus isolated in the form of a brown solid. (3g - yield 4.5%). The 1H NMR spectrum and the mass spectrum confirm the structure of the expected compound 2. 1H NMR (MeOD): 0.83-1.00 (m, 6H); 1.32 (s, 6H); 1.56-1.79 (m, 4H); 2.69 (s, 3H); 3.26-3.41 (m, 9H); 4.43 (s, 2H); 4.96-5.09 (m, 1H). Spectrom. mass: detected = 230 - expected for [C₁HH₂NNO₂] ± = 230 Example 3: preparation of compound 6 ## STR1 ## ## STR2 ## A mixture of betaine (A) (55.4 g, 0.47 mol), 3-methyl-1-butanol (210 ml) and methanesulfonic acid (36.8 ml) is heated at 140 ° C. for 7 h under an inert atmosphere (N 2). . The reaction medium is stirred at room temperature for 17 h, the excess acid is neutralized by addition of a saturated aqueous solution of betaine. The water contained is then removed by evaporation under reduced pressure, and the betaine salts are filtered. The filtrate is concentrated to dryness under reduced pressure. The residue is taken up in heptane. The product 6 is thus isolated in the form of a white solid. (76.4g - 57% yield) The 1 H NMR spectrum and the mass spectrum confirm the expected structure of compound 6. 1H NMR (DMSO): 0.82-0.94 (d, 6H); 1.45-1.56 (td, 2H); 1.56-1.72 (m, 1H); 2.32-2.41 (m, 3H); 3.17-3.29 (m, 9H); 4.17-4.27 (m, 2H); 4.40-4.46 (m, 2H) Spectrom. mass: detected = 188 - expected for [C10H22NO2] ± = 188 Example 4: preparation of compound 7 CH I, 3 OCH3 H3C-N'r & CH7 A mixture of compound 6, 10g of DOWEX 1x2 ion exchange resin 200 and 20 ml of methanol are stirred at ambient temperature for 24 hours. The resin is removed by filtration and the filtrate is concentrated by evaporation under reduced pressure. The product 7 is thus isolated in the form of a white gray solid. (2 g - 69%) The 1 H NMR spectrum and the mass spectrum confirm the structure of the expected compound 7.

1 H NMR (MeO D): 0.88-1.02 (d, 6H); 1.54-1.63 (td, 2H); 1.63-1.81 (m, 1H); 3,273.41 (m, 9H); 4.27-4.38 (t, 2H); 4.38-4.47 (m, 2H). Spectrom. mass: detected = 188 - expected for [C₁HH₂₂NO₂] ± = 188 Example 5: preparation of the compound ## STR2 ## A mixture of betaine (A) ( 4 g, 34.1 mmol), allyl alcohol (18.6 ml) and methanesulphonic acid (2.9 ml) is heated at 80 ° C. for 5 h under an inert atmosphere (N 2). After returning to ambient temperature, the excess of acid is neutralized by adding a saturated aqueous solution of betaine. This mixture is then concentrated to dryness by evaporation under reduced pressure. The residue is taken up in acetone to redissolve the product. After filtration of the betaine salts, the filtrate is concentrated by evaporation under reduced pressure. The crude reaction product is purified by recrystallization from n-heptane. The product 4 is thus isolated in the form of a light yellow solid. (5g - 58%) The 1 H NMR spectrum and the mass spectrum confirm the structure of the expected compound 4. 1 H NMR (MeOD): 2.69 (s, 3H); 3.25-3.42 (m, 9H); 4.43 (s, 2H); 4.74-4.85 (d, 2H); 5.28-5.54 (m, 2H); 5.94-6.14 (m, 1H). Spectrom. mass: detected = 158 - expected for [C8H16NO2] ± = 158 CI30 Example 6: preparation of the compound 5 o CH 3 H, CS-0 wo / N-CH 3 '1 / H 3 C I 0 CH 3 A mixture of betaine (A) (2 g, 16.9 mmol), n-hexanol (8 ml) and methanesulfonic acid (1.4 ml) is heated at 140 ° C. for 8 hours under an inert atmosphere (N 2). After returning to ambient temperature, the excess of acid is neutralized by adding a saturated aqueous solution of betaine. This mixture is then concentrated to dryness by evaporation under reduced pressure. The residue is taken up in acetone to redissolve the product. After filtration of the betaine salts, the filtrate is concentrated by evaporation under reduced pressure. The crude reaction product is purified by recrystallization from n-heptane. The product is thus isolated in the form of a white solid. (2.6g - 52% yield). The 1 H NMR spectrum and the mass spectrum confirm the structure of the expected compound. 1H NMR (MeOD): 0.87-1.00 (m, 3H); 1.29-1.51 (m, 6H); 1.64-1.80 (q, 2H); 2.71 (s, 3H); 3.35 (s, 9H); 4.24-4.35 (t, 2H); 4.41 (s, 2H). Spectrom. mass: detected = 202 - expected for [C11H24NO2] ± = 202 EXAMPLE 7 Preparation of Compound 8 0F13 0 H3C / N --- CH3 \\ Li r - S --- 0 0- + 1 13 ... A mixture of betaine (A) (20 g, 0.17 mol), and benzyl alcohol (277 g) is heated to 40 ° C. After solubilization of betaine in benzyl alcohol, methanesulfonic acid (14 ml) is added and the mixture is stirred at 120 ° C. for 24 hours. The reaction medium is then distilled at 140 ° C. under vacuum for 4 hours. The residue is precipitated in diethyl ether and filtered. The product 8 is thus isolated after drying under vacuum at 30 ° C in the form of a beige solid. (16.03g - 31% yield). The 1 H NMR spectrum confirms the structure of the expected compound 8. 1H NMR (DMSO): 2.30 (s, 3H); 3.21 (s, 9H); 4.51 (s, 2H); 5.21 (s, 2H); 7.25-7.42 (m, 5H).

EXAMPLE 8 Preparation of Compound 9 H3C-S-O-II H3C-N CH I, 1-1-3 A mixture of betaine (A) (150 g, 1.28 mol), isopropanol (615 g) and methanesulfonic acid (91mL) is heated to 130 ° C with stirring while distilling the isopropanol continuously and with continual addition of isopropanol. After 24h, 100 ml of methanesulphonic acid are added. After 48 hours and follow the formation of the product by NMR 75 ml of methanesulfonic acid are added. After 72h, the reaction medium is filtered and the filtrate is concentrated by evaporation under reduced pressure. The reaction crude is purified by adding betaine in isopropanol to neutralize the residual acid. The mixture is centrifuged, the pellet is removed and the liquid phase is evaporated under reduced pressure. The product 8 is thus isolated in the form of a white solid. (107g - 33% yield). The 1H NMR spectrum and the mass spectrum confirm the structure of the expected compound 8.

1H NMR (DMSO): 1.21-1.29 (d, 6H); 3.22 (s, 9H); 4.39 (s, 2H), 5.00-5.12 (m, 1H) Spectrom. mass: detected = 160 - expected for [C8H18NO2] ± = 160 Example 9: preparation of the compound 10 H3C-S-0 0 0 10 _H3C- ./`c- 3 CH3 0 cH3 I, a mixture of betaine (A) (120g, 1.02mol), and ethanol (897mL) was heated at 50 ° C for 5h. The methanesulfonic acid (80 ml) is added in 45 minutes with stirring. The reaction medium is then heated under reflux (80 ° C.) for 18 hours before being brought back to ambient temperature. After 48 hours at room temperature, unreacted betaine is filtered. The filtrate is concentrated by evaporation under reduced pressure. The product 10 is thus isolated in the form of a white solid. The conversion of betaine to ester, estimated by 1 H NMR, is 96 mol%. The 1H NMR spectrum confirms the structure of the expected compound. CH 3 H NMR 1 H (D 2 O): 1.2 (t, 3H); 2.6-2.8 (s, 3H); 3.2-3.4 (s, 9H); 4.2-4.4 (m, 4H) Example 10: Preparation of compound 11 0 H3C-S-O 10 A mixture of betaine (A) (30 g, 0.25 mol), 2-methyl-1-butanol (300g, 4mol) is heated to 80 ° C. Once the mixture is homogeneous, methanesulfonic acid (29.5g, 0.30mol) is added. The reaction medium is heated at 130 ° C. for 28 hours. The conversion of betaine to ester is 90 mol% (followed by 1H NMR). The reaction medium is placed at 4 ° C. in order to precipitate the residual betaine. The filtrate is then concentrated and the product is precipitated in diethyl ether. It is isolated in the form of a white solid. The 1H NMR spectrum confirms the structure of the expected compound 11. 1 H NMR (D 2 O): 0.8-1 (d, 6H); 1.8-2 (m, 1H); 2.6-2.8 (s, 3H); 3.2-3.4 (s, 9H); 4 (dd, 2H); 4.2-4.4 (s, 2H) EXAMPLE 11 Preparation of Compound 12 CH3 0 I + El3C-10CH3 CH3 CH1,3 N-CH1 3 CH3 12 1st Intermediate Step (B) CKs, C1 ACN CI HN) LS II / 1 g 0 CH, C12 (A) TEA (B) A mixture of betaine (A) (2g, 16.9mol), thionyl chloride (1.84mL) and acetonitrile (20mL) is heated to 50 ° C. ° C for 2h, under an inert atmosphere (Ar). This mixture is then concentrated to dryness by evaporation under reduced pressure. The residue is suspended in dichloromethane and then cooled to 0 ° C. After the addition of 2-mercaptothiazoline (2.26 g) and triethylamine (2.57 ml), the reaction medium is brought up to room temperature and stirred for 17 h. After filtration, the precipitate is washed twice with dichloromethane. The intermediate (B) is thus isolated in the form of a solid. (2.1 g - 49% yield) The 1 H NMR spectrum confirms the structure of the expected intermediate (B). 1H NMR (DMSO): 3.26-3.30 (m, 9H); 3.47-3.55 (t, 2H); 4.55-4.63 (t, 2H); 5.22 (s, 2H) 2nd step c 1 + (1) 1 + 1 THF / I 0 (B) (12) A mixture of intermediate (B) (337 mg, 1.32 mmol) ), octadecylamine (250mg) and THF (20mL) is stirred at room temperature for 17h under an inert atmosphere (Ar).

The insoluble material is filtered and the precipitate is washed with dichloromethane. The precipitate is purified by recrystallization from an ethanol / dichloromethane mixture. The product 12 is thus isolated in the form of a beige fluffy solid. (248mg - 69% yield). Example 12 Activity on C. xerosis The antimicrobial activity of compound 6 at 1% w / w was evaluated in vitro on Corynebacterium xerosis. The principle of the method is as follows: the raw materials are put in contact with the bacteria in a suitable medium, and after a contact time of 24 hours, the reduction in the number of revivable germs is measured, compared to a placebo without said raw materials. After 24 hours, the reduction in number of log relative to the placebo is 3. The inventors consider that the compound 6 of formula (I) has a deodorant activity.

EXAMPLE 13 Aerosol deodorant formulation Compound 6 1% Silicone 3% Perfume 0.75% Isobutane and propane 45% Ethyl alcohol qs 100% Example 14 Antiperspirant formulation roll-on Compound 6 1% Aluminum Hydrochloride 15% PPG-15 Stearyl Ether 2% Silicone 1.25% Cetareth-33 2% Fragrance 0.7% Water qs 100`) / 0

Claims (15)

Use of at least one compound of the following formula (I) or one of its optical isomers, as a deodorant agent: ## STR1 ## wherein X represents an organic or inorganic anion; Y is 0 or NR '; R denotes: a linear or branched, saturated or unsaturated C 2 -C 22 alkyl radical; O an aralkyl radical, in which the alkyl is C1-C22, linear or branched, saturated or unsaturated, in particular an aralkyl radical, the aryl part of which is a phenyl radical optionally substituted with 1 to 4 linear or branched C1-C4 alkyl radicals; ; An aryl radical, in particular a phenyl radical optionally substituted with 1 to 4 linear or branched C1-C4 alkyl radicals; R 'denotes: O a hydrogen atom; O a linear or branched, saturated or unsaturated C 1 -C 22 alkyl radical; An aralkyl radical, in which the alkyl is C1-C22, linear or branched, saturated or unsaturated, in particular an aralkyl radical, the aryl part of which is a phenyl radical optionally substituted with 1 to 4 linear C1-C4 alkyl radicals; branched; An aryl radical, in particular a phenyl radical optionally substituted with 1 to 4 linear or branched C1-C4 alkyl radicals. 2. Use according to claim 1, characterized in that the compound of formula (I) is chosen from the compounds for which: R denotes a linear or branched, saturated or unsaturated C 2 -C 22 alkyl radical; Y is 0 or NR '; R 'denotes: O a hydrogen atom O a linear or branched, saturated or unsaturated C1-C22 alkyl radical. (I) 535 3.- Use according to claim 1 or 2, characterized in that the compound of formula (I) is chosen from the compounds for which: - R denotes a linear or branched alkyl radical, saturated or unsaturated at 02-022, and / or or - Y represents 0 or NH. 4.- Use according to any one of the preceding claims, characterized in that X- denotes: halide, such as for example chloride or bromide, and preferably chloride; sulfate, methanesulfonate, citrate, lactate, acetate, and any combination thereof. 5. Use according to any one of the preceding claims, characterized in that the compound of formula (I) is chosen from the following compounds: ## STR1 ## ## STR2 ## ## STR1 ## ## STR2 ## ## STR1 ## ## STR3 ## ## STR2 ## Wherein X X is as defined in claim 1 or 4. 6. Use according to any one of the preceding claims, characterized in that the compound of formula (I) is chosen from the following compounds: ## STR2 ## ## EQU0000 ## ## STR0000 ## where ## STR2 ## where ## STR2 ## ## STR2 ## ## STR2 ## ## STR1 ## N0 II I 0 0 I, o -S-0-Nc) / "/ Il I 0 7. Use according to any one of claims 1 to 6, characterized in that the compound or compounds of formula (I) are present in a composition comprising a physiologically acceptable medium. 8. A compound selected from the following compounds: 1-13c 0 CH I ± 3 X- H CH3, X- denoting an organic or inorganic anion; Wherein Z- represents an organic or inorganic anion with the exception of chloride, and preferably selected from bromide, sulfate, methanesulfonate, citrate, lactate, acetate; or one of their optical isomers. 9. A compound according to claim 8, characterized in that it is chosen from the following compounds: ## STR2 ## 0 H - -S-O \ + O H - N 0/0 or one of their optical isomers. 10. A compound according to claim 8, characterized in that it is represented by the following formula: ## STR2 ## representing an organic or inorganic anion with the exception of chloride, and preferably chosen from bromide, sulphate, methanesulphonate, citrate, lactate, acetate, and more preferably methanesulphonate; or one of its optical isomers. 11. Composition, in particular a cosmetic composition comprising, in a physiologically acceptable medium, at least one compound of formula (I) as defined according to any one of Claims 1 to 10, in combination with at least one antiperspirant active agent and / or at least one other deodorant active agent in a physiologically acceptable medium. 12. Composition, in particular a cosmetic composition, comprising in a physiologically acceptable medium at least one compound of formula (I), as defined according to any one of Claims 1 to 10, optionally in combination with at least one antiperspirant active agent. and / or at least one other deodorant active agent in a physiologically acceptable medium, said composition being accompanied by a package or information notice presenting visual information concerning the treatment of odors and / or perspiration of a human being, and / or information on the presence of at least one antiperspirant active agent and / or at least one deodorant active agent, possibly among other visual information. 13.- Aerosol device consisting of: (A) at least one container comprising a composition as defined in claim 11 or 12, (B) at least one propellant and at least one means for dispensing said composition in aerosol form . 14.- composition as defined in claim 11 or 12, or device comprising it, accompanied (e) packaging ("packaging") or information notice including, possibly among other visual information, the mention of the presence of one or more of the compounds as defined in any one of claims 1 to 10, optionally in combination with at least one antiperspirant active and / or at least one other deodorant active, said packaging or said information'information presenting visual information concerning the treatment of odors and / or perspiration of a human being and / or information on the presence of at least one antiperspirant active and / or at least one deodorant active. 15- A cosmetic method for treating body odors, in particular axillary, comprising applying to the surface of the skin a composition comprising, in a physiologically acceptable medium, at least one compound of formula (I) as defined according to any one of the claims 1 to 10, or a composition as defined in any one of claims 11 to 12.